A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

Summary

This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period.

Timeline

Start

2021-08-25

Primary completion

2023-02-21

Completion

2023-02-21

Publications

• Maksymowych WP, Yeshokumar A, Cerullo E, Lambert RGW, Sliwinska-Stanczyk P, Klimiuk P, Kepich R, Pachai C, Zhu M, Liu J, Landis J, Goti V, Greenberg S. Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis. RMD Open. 2026 May 21;12(2):e006527. doi: 10.1136/rmdopen-2025-006527.

Drugs

Indications